Abeona Therapeutics (ABEO) Receives a Hold from Leerink Partners

In a report issued on January 28, Mani Foroohar from Leerink Partners maintained a Hold rating on Abeona Therapeutics (ABEOResearch Report), with a price target of $1.00. The company’s shares closed last Monday at $0.26, close to its 52-week low of $0.21.

According to, Foroohar has 0 stars on 0-5 stars ranking scale with an average return of -17.9% and a 37.4% success rate. Foroohar covers the Healthcare sector, focusing on stocks such as Recursion Pharmaceuticals, Arrowhead Pharmaceuticals, and 4D Molecular Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Abeona Therapeutics with a $4.00 average price target.

See Insiders’ Hot Stocks on TipRanks >>

Abeona Therapeutics’ market cap is currently $38.5M and has a P/E ratio of -0.46.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in New York, NY.

Read More on ABEO:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More